Allon Hammered as Davunetide Misses in a Pivotal PSP Trial
By Staff Reports
Tuesday, December 18, 2012
Shares of Canadian firm Allon Therapeutics Inc. lost 94 percent of their value Tuesday on news that the company's pivotal study of lead candidate davunetide failed to show an effect in patients with progressive supranuclear palsy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.